Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside. ↗

November 06, 2023

The company was expected to report a third-quarter loss and plummeting sales.

Via Investor's Business Daily

This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play' ↗

November 06, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said DocuSign, Inc.

Via Benzinga

CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross’ Tongue ↗

November 05, 2023

Bill Gross, the Bond King, is wading into the world of equity arbitrage with these three stocks - but are they worth the risk for investors?

Via InvestorPlace

Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years ↗

November 03, 2023

Via Benzinga

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 03, 2023

From Seagen Inc.

Via Business Wire

This High-Yield Dividend Stock Is a Proven Wealth Creator ↗

November 02, 2023

This heavily sold-off pharma stock is a bargain.

Via The Motley Fool

Looking At Seagen's Recent Unusual Options Activity ↗

November 01, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 02, 2023

Via Benzinga

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

November 02, 2023

From Seagen Inc.

Via Business Wire

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

November 01, 2023

From Seagen Inc.

Via Business Wire

The 7 Most Undervalued Long-Term Stocks to Buy: October 2023 ↗

October 29, 2023

Equities remain under pressure, but if you’re looking to be a contrarian investor, it’s a good time to look for undervalued long-term stocks.

Via InvestorPlace

(SGEN) - Analyzing Seagen's Short Interest ↗

October 23, 2023

Via Benzinga

Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High

October 23, 2023

Via Investor Brand Network

Earnings Scheduled For November 1, 2023 ↗

November 01, 2023

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.

Via Benzinga

Earnings Outlook For Seagen ↗

October 31, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 25, 2023

Via Benzinga

Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Tuesday Session

October 24, 2023

Via Investor Brand Network

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks ↗

October 22, 2023

The companies studied a combination of Keytruda and Padcev in bladder cancer patients.

Via Investor's Business Daily

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

October 22, 2023

From Seagen Inc.

Via Business Wire

Here's How Much $1000 Invested In Seagen 5 Years Ago Would Be Worth Today ↗

October 17, 2023

Via Benzinga

How Is The Market Feeling About Seagen? ↗

October 06, 2023

Via Benzinga

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

October 22, 2023

From Seagen Inc.

Via Business Wire

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗

October 21, 2023

The venerable pharmaceutical companies' shares have slumped this year.

Via The Motley Fool

Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

October 20, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END

Via FinancialNewsMedia

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

October 16, 2023

From Seagen Inc.

Via Business Wire

Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

October 12, 2023

From Seagen Inc.

Via Business Wire

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

October 11, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

Via FinancialNewsMedia

10 Health Care Stocks Whale Activity In Today's Session ↗

October 09, 2023

Via Benzinga

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗

October 05, 2023

Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant...

Via Benzinga

2 High-Yield Dividend Stocks to Buy in October ↗

October 04, 2023

These two high-yield dividend stocks are too cheap to ignore.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Seagen Inc. - Common Stock (NQ:SGEN)

All News about Seagen Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today